At Vitafoods Europe 2025, Epax captured attention with the launch of EPAX® Evolve 05—the world’s first commercially available very-long-chain polyunsaturated fatty acid (VLC‑PUFA) concentrate. This breakthrough opens the door to a new class of omega‑3s beyond traditional EPA and DHA.
What Are VLC‑PUFAs?
VLC‑PUFAs are omega‑3s with chain lengths of 24 carbon atoms or more (C24–C28). Though naturally present in trace amounts in fish oil, they’ve been historically difficult to extract and study—until now.
Why they matter:
Emerging research suggests VLC‑PUFAs may support:
-
Cognitive and visual health
-
Skin health & radiance
-
Muscle strength and bone health
-
Male fertility
These promising benefits, coupled with Epax’s ability to concentrate them, mark a major leap for the nutraceutical sector.
What Makes EPAX® Evolve 05 Unique?
-
Contains ~10x more VLC‑PUFAs than standard fish oil
-
Part of the NovusLipid™ range, Epax’s line of next-gen marine lipid ingredients
-
Developed through a decade of R&D and patented processes
This innovation allows brands to explore new product categories and health claims with truly differentiated omega-3s.
“The stage is set for a new era for omega-3,” said Bjørn Refsum, CEO of Epax. With Evolve 05, the company is pushing the boundaries of marine lipid science and offering supplement brands a powerful new ingredient to drive formulation innovation.
